Portal de Periódicos da CAPES

Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis

2003; Elsevier BV; Volume: 48; Issue: 1 Linguagem: Inglês

10.1067/mjd.2003.130

1097-6787

Kim Papp, Lyn Guenther, B. Boyden, Frederik Grønhøj Larsen, Rauno J. Harvima, Jean Jacques Guilhou, Roland Kaufmann, Sarah Rogers, P.C.M. van de Kerkhof, Leif I. Hanssen, E Tegner, Günter Burg, David Talbot, Anthony C. Chu,

Allergic Rhinitis and Sensitization

Abstract Background: Calcipotriene and betamethasone dipropionate are topical treatments for psoriasis vulgaris. Their mode of action is different. Improved risk/benefit may result with concomitant use of the two compounds together. A new vehicle has been created with the objective of obtaining optimal stability of both calcipotriene and betamethasone dipropionate in the combination product. Objective: We compared the clinical efficacy of a fixed combination of calcipotriene and betamethasone dipropionate in a new vehicle to calcipotriene in the new vehicle, betamethasone in the new vehicle, and the new vehicle alone. Methods: This was an international, multicenter, prospective, randomized, double-blind, parallel-group, 4-week study in patients with psoriasis vulgaris amenable to topical treatment. Results: The mean percentage reduction in PASI from baseline to end of treatment was 73.2% in the combination group (n = 301), 48.8% in the calcipotriene group (n = 308), 63.1% in the betamethasone dipropionate group (n = 312) and 28.8% in the new vehicle group (n = 107), ( P < .001). The mean percentage reduction in PASI during the first week was 48.1%, 28.4%, 41.4%, and 21.5%, respectively ( P < .001). Conclusion: A combination product of calcipotriene 50 μg/g and betamethasone dipropionate 0.5 mg/g in the new vehicle shows superior efficacy with a more rapid onset of action than the new vehicle containing either constituent alone in the treatment of psoriasis vulgaris. (J Am Acad Dermatol 2003;48:48-54.)